Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy

Jim O'Prey, Simon Wilkinson, Kevin M Ryan

Research output: Contribution to journalArticlepeer-review

Abstract

Adenoviruses for gene or oncolytic therapy are under development. Notable among these strategies is adenoviral delivery of the tumor suppressor p53. Since all therapeutics have limitations in certain settings, we have undertaken retroviral suppressor screens to identify genes conferring resistance to adenovirus-delivered p53. These studies identified the tumor antigen LRRC15, which is frequently overexpressed in multiple tumor types, as a repressor of cell death due to adenoviral p53. LRRC15, however, does not impede p53 function per se but impedes adenoviral infection. Specifically, LRRC15 causes redistribution of the coxsackievirus-adenovirus receptor away from the cell surface. This effect is manifested in less adenoviral binding to the surfaces of LRRC15-expressing cells. This discovery, therefore, not only is important for understanding adenoviral biology but also has potentially important implications for adenovirus-based anticancer therapeutics.
Original languageEnglish
Pages (from-to)5933-9
Number of pages7
JournalJournal of Virology
Volume82
Issue number12
DOIs
Publication statusPublished - 2008

Fingerprint

Dive into the research topics of 'Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy'. Together they form a unique fingerprint.

Cite this